337 related articles for article (PubMed ID: 29153485)
1. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
3. Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.
Heise T; Kaplan K; Haahr HL
J Diabetes Sci Technol; 2018 Mar; 12(2):356-363. PubMed ID: 28946756
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
[TBL] [Abstract][Full Text] [Related]
5. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Shiramoto M; Eto T; Irie S; Fukuzaki A; Teichert L; Tillner J; Takahashi Y; Koyama M; Dahmen R; Heise T; Becker RH
Diabetes Obes Metab; 2015 Mar; 17(3):254-60. PubMed ID: 25425297
[TBL] [Abstract][Full Text] [Related]
6. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
7.
Schiavon M; Visentin R; Giegerich C; Sieber J; Dalla Man C; Cobelli C; Klabunde T
Diabetes Technol Ther; 2020 Aug; 22(8):553-561. PubMed ID: 32125178
[No Abstract] [Full Text] [Related]
8. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
Becker RH; Dahmen R; Bergmann K; Lehmann A; Jax T; Heise T
Diabetes Care; 2015 Apr; 38(4):637-43. PubMed ID: 25150159
[TBL] [Abstract][Full Text] [Related]
9. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.
Korsatko S; Deller S; Mader JK; Glettler K; Koehler G; Treiber G; Urschitz M; Wolf M; Hastrup H; Søndergaard F; Haahr H; Pieber TR
Drugs Aging; 2014 Jan; 31(1):47-53. PubMed ID: 24263619
[TBL] [Abstract][Full Text] [Related]
10. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml.
Becker RH; Nowotny I; Teichert L; Bergmann K; Kapitza C
Diabetes Obes Metab; 2015 Mar; 17(3):261-7. PubMed ID: 25425394
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL
Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Pascucci C; Gambelunghe A; Bolli GB; Fanelli CG; Porcellati F
Diabetes Care; 2021 Jan; 44(1):125-132. PubMed ID: 33444161
[TBL] [Abstract][Full Text] [Related]
12. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
13. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
Porcellati F; Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Curti G; Bolli GB; Fanelli CG
Diabetes Care; 2019 Jan; 42(1):85-92. PubMed ID: 30305345
[TBL] [Abstract][Full Text] [Related]
15. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
Haahr H; Sasaki T; Bardtrum L; Ikushima I
J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
[TBL] [Abstract][Full Text] [Related]
16. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
[TBL] [Abstract][Full Text] [Related]
17. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state.
Komuro M; Inoue G; Tabata M; Yamada Y; Atsuda K; Matsubara H; Irie J; Uchida J; Nakajima C; Izumi H; Shimada M; Yamada S
J Diabetes Sci Technol; 2015 May; 9(3):632-8. PubMed ID: 25526758
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
[TBL] [Abstract][Full Text] [Related]
19. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.
Heise T; Hermanski L; Nosek L; Feldman A; Rasmussen S; Haahr H
Diabetes Obes Metab; 2012 Sep; 14(9):859-64. PubMed ID: 22594461
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.
Hompesch M; Morrow L; Watkins E; Roepstorff C; Thomsen HF; Haahr H
Clin Ther; 2014 Apr; 36(4):507-15. PubMed ID: 24508419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]